Antheia
Kristy has over 15 years of experience in the field of synthetic biology, focusing on yeast metabolic engineering for the production of small molecules. She did the founding work on the benzylisoquinoline alkaloid pathway during her graduate studies and gained valuable industry experience at Amyris and Lygos. Kristy is an expert in tool development, high-throughput screening, and host strain and heterologous pathway engineering. She believes that all plant-derived medicines will ultimately be produced using microbial fermentation technology.
This person is not in any offices
Antheia
Antheia is unlocking the medicinal power of nature. Its synthetic biology platform surpasses the limits of conventional drug discovery and manufacturing through a novel approach to whole cell engineering reconstructing complex molecules in yeast to bring to market next generation plant inspired medicines.